Motilal Oswal Financial Services has a buy call on PI Industries with a target price of Rs 5,200. The current market price of PI Industries Ltd. is Rs 4,199.
PI Industries, incorporated in 1946, is a Large Cap company with a market cap of Rs 63225.49 crore, operating in the Pesticides/Agro Chemicals sector. PI Industries' key products/revenue segments include Agri inputs, Export Incentives, Sale of services and Scrap for the year ending 31-Mar-2024.
Financials For the quarter ended 30-09-2024, the company has reported a Consolidated Total Income of Rs 2343.20 crore, up 9.41% from last quarter Total Income of Rs 2141.
60 crore and up 8.29% from last year same quarter's Total Income of Rs 2163.80 crore.
The company has reported net profit after tax of Rs 507.50 crore in the latest quarter. Investment Rationale PI Industries continues to deliver modest growth amidst challenging business environment.
Although demand is likely to be better for domestic crop protection and pharma business in 2H, overall global industry challenges have tapered down the near-term growth outlook for the company. Stock Trading ROC Made Easy: Master Course for ROC Stock Indicator By - Souradeep Dey, Equity and Commodity Trader, Trainer View Program Stock Trading Technical Analysis for Everyone - Technical Analysis Course By - Abhijit Paul, Technical Research Head, Fund Manager- ICICI Securities View Program Stock Trading Introduction to Technical Analysis & Candlestick Theory By - Dinesh Nagpal, Full Time Trader, Ichimoku & Trading Psychology Expert View Program Stock Trading Technical Analysis Made Easy: Online Certification Course By - Souradeep Dey, Equity and Commodity Trader, Trainer View Program Stock Trading Point & Figure Chart Mastery: A Comprehensive Trading Guide By - Mukta Dhamankar, Full Time Trader, 15 Years Experience, Instructor View Program Stock Trading Options Scalping Made Easy By - Sivakumar Jayachandran, Ace Scalper View Program Stock Trading Commodity Markets Made Easy: Commodity Trading Course By - elearnmarkets, Financial Education by StockEdge View Program Stock Trading Cryptocurrency Made Easy: Cryptocurrency Course By - elearnmarkets, Financial Education by StockEdge View Program Stock Trading Options Trading Made Easy: Options Trading Course By - Anirudh Saraf, Founder- Saraf A & Associates, Chartered Accountant View Program Stock Trading Candlesticks Made Easy: Candlestick Pattern Course By - elearnmarkets, Financial Education by StockEdge View Program Stock Trading A2Z of Stock Trading - Online Stock Trading Course By - elearnmarkets, Financial Education by StockEdge View Program Stock Trading Market 103: Mastering Trends with RMI and Techno-Funda Insights By - Rohit Srivastava, Founder- Indiacharts.com View Program Stock Trading Complete Guide to Stock Market Trading: From Basics to Advanced By - Harneet Singh Kharbanda, Full Time Trader View Program However, Motilal Oswal Financial Services, still believes that PI has enough levers in place to deliver healthy growth in medium to long term, led by: 1) consistent growth momentum in the CSM business, driven by the rising pace of commercialization of new molecules and a sale ramp-up in existing molecules; 2) product launches in the domestic market (six to seven new launches in FY25); and 3) ramping up of the pharma API and CDMO segments.
The brokerage expects a CAGR of 13%/16%/11% in revenue/EBITDA/adj. PAT over FY24-27. They reiterates a BUY with a target price of Rs 5,200 (35x on Dec?26 EPS).
Promoter/FII Holdings Promoters held 46.09 per cent stake in the company as of 30-Sep-2024, while FIIs owned 19.02 per cent, DIIs 26.
16 per cent. (You can now subscribe to our ETMarkets WhatsApp channel ).
Business
Buy PI Industries, target price Rs 5,200: Motilal Oswal Financial Services
Motilal Oswal Financial Services recommends buying PI Industries stock. They project a target price of Rs 5,200. The company shows promise despite challenges in the global industry. PI Industries is expected to grow steadily. This growth will be driven by new molecules and product launches. The company's pharma division is also expected to expand.